Hosted on MSN
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline
Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X-TOLE2 study of azetukalner for focal onset seizures with top line data readout in early 2026; ...
Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no ...
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy ...
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...
Hosted on MSN
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data
・The analyst noted that Ocugen has three clinical stage programs in rare and non-rare retinal diseases including OCU400, OCU410ST and OCU410. ・According to data from Koyfin, all six of the six ...
BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully ...
Roivant Sciences Ltd. (NASDAQ: ROIV) set out its long-term vision on Tuesday during its Investor Day, outlining accelerated timelines and expanded commercial ambitions across several late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results